Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

NCT04557046 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1134

Last updated 2023-12-26

No results posted yet for this study

Summary

Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Nasal Swab

Collection of one more nasal swabs

DIAGNOSTIC_TEST

Nasopharyngeal swab

Collection of one more nasopharyngeal swabs

DIAGNOSTIC_TEST

Throat swab

Collection of one more throat swabs

DIAGNOSTIC_TEST

Fingerstick

Collection of capillary blood from one or more fingersticks

DIAGNOSTIC_TEST

Saliva specimen

Collection of free drool

Sponsors & Collaborators

  • LumiraDx UK Limited

    lead INDUSTRY

Principal Investigators

  • Christopher Chappel · Chappel Group

  • Robert Rosen · Ardmore Family Practice

  • Andre Gvozden · Gvozden Pediatrics

  • Madhavi Ampajwala · Village Health Partners

  • Edward Zissman · Pediatric Associates of Altamonte Springs

  • Melanie Hoppers · Physicians Quality Care of Jackson

  • Kimberley Henderson · Good Samaritan Minute Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2021-03-24
Completion
2024-03-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04557046 on ClinicalTrials.gov